Veridian Biotechnology Limited (VBL) is committed to improving patients’ lives by delivering innovative and sustainable technologies. Located in the Hong Kong Science and Technology Park, our key technologies include handling large protein drugs and employing mammalian cell factories to produce biosimilars and new drugs to treat complex human diseases, such as bleeding disorders and cancer. Leveraging our global network of scientists, we are working to develop versatile medical interventions with improved efficacy and bioactivity. Our first product line contains biosimilars and revolutionary blood coagulation factors to treat inherited and acquired bleeding disorders.